Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Jul 15;311(6998):156–158. doi: 10.1136/bmj.311.6998.156

HIV positive patients first presenting with an AIDS defining illness: characteristics and survival.

M C Poznansky 1, R Coker 1, C Skinner 1, A Hill 1, S Bailey 1, L Whitaker 1, A Renton 1, J Weber 1
PMCID: PMC2550220  PMID: 7613426

Abstract

OBJECTIVES--To study the presentation and survival of patients who present with their first diagnosis of being HIV positive at the same time as their AIDS defining illness. DESIGN--Retrospective study of patients presenting with AIDS between 1991 and 1993. SETTING--Department of genitourinary medicine, St Mary's Hospital, London. MAIN OUTCOME MEASURES--AIDS defining illness at presentation and survival after diagnosis of AIDS. RESULTS--Between January 1991 and December 1993, 97 out of 436 patients (22%) presented with their first AIDS defining illness coincident with their first positive result of an HIV test (group B). The remaining 339 patients (78%) had tested positive for HIV-1 infection within the previous eight years and had consequently been followed up in clinics before developing their first AIDS defining illness (group A). The two groups of patients did not differ in age and sex distribution, risk factors for HIV-1 infection, nationality, country of origin, or haematological variables determined at the time of the AIDS defining illness. However, the defining illnesses differed between the two groups. Illnesses associated with severe immunodeficiency (the wasting syndrome, cryptosporidiosis, and cytomegalovirus infection) were seen almost exclusively in group A whereas extrapulmonary tuberculosis and Pneumocystis carinii pneumonia were more common in group B. The survival of patients in group B after the onset of AIDS was significantly longer than that of patients in group A as determined by Kaplan-Meier log rank analysis (P = 0.0026). CONCLUSIONS--Subjects who are HIV positive and present late are a challenge to the control of the spread of HIV infection because they progress from asymptomatic HIV infection to AIDS without receiving health care. The finding that presentation with an AIDS defining illness coincident with a positive result in an HIV test did not have a detrimental effect on survival gives insights into the effects of medical intervention on disease progression after a diagnosis of AIDS.

Full text

PDF
156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacchetti P., Osmond D., Chaisson R. E., Dritz S., Rutherford G. W., Swig L., Moss A. R. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis. 1988 May;157(5):1044–1047. doi: 10.1093/infdis/157.5.1044. [DOI] [PubMed] [Google Scholar]
  2. Coker R. J., Nieman R., McBride M., Mitchell D. M., Harris J. R., Weber J. N. Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet. 1992 Oct 31;340(8827):1099–1099. doi: 10.1016/0140-6736(92)93120-c. [DOI] [PubMed] [Google Scholar]
  3. Cooper D. A., Gatell J. M., Kroon S., Clumeck N., Millard J., Goebel F. D., Bruun J. N., Stingl G., Melville R. L., González-Lahoz J. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 1993 Jul 29;329(5):297–303. doi: 10.1056/NEJM199307293290501. [DOI] [PubMed] [Google Scholar]
  4. Drotman D. P. Earlier diagnosis of human immunodeficiency virus (HIV) infection and more counseling. Ann Intern Med. 1989 May 1;110(9):680–681. doi: 10.7326/0003-4819-110-9-680. [DOI] [PubMed] [Google Scholar]
  5. Graham N. M., Zeger S. L., Park L. P., Phair J. P., Detels R., Vermund S. H., Ho M., Saah A. J. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet. 1991 Aug 3;338(8762):265–269. doi: 10.1016/0140-6736(91)90414-k. [DOI] [PubMed] [Google Scholar]
  6. Hanson D. L., Horsburgh C. R., Jr, Fann S. A., Havlik J. A., Thompson S. E., 3rd Survival prognosis of HIV-infected patients. J Acquir Immune Defic Syndr. 1993 Jun;6(6):624–629. [PubMed] [Google Scholar]
  7. Oddone E. Z., Cowper P., Hamilton J. D., Matchar D. B., Hartigan P., Samsa G., Simberkoff M., Feussner J. R. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ. 1993 Nov 20;307(6915):1322–1325. doi: 10.1136/bmj.307.6915.1322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Peters B. S., Beck E. J., Coleman D. G., Wadsworth M. J., McGuinness O., Harris J. R., Pinching A. J. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ. 1991 Jan 26;302(6770):203–207. doi: 10.1136/bmj.302.6770.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Porter K., Wall P. G., Evans B. G. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ. 1993 Jul 3;307(6895):20–23. doi: 10.1136/bmj.307.6895.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297–1302. doi: 10.1056/NEJM198711193172101. [DOI] [PubMed] [Google Scholar]
  11. Volberding P. A., Lagakos S. W., Grimes J. M., Stein D. S., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S., Phair J. P., Mitsuyasu R. T. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10;272(6):437–442. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES